Lower Limb PAD with Intermittent Claudication: What to Do When First-Line Therapy Has Not Improved Walking Distance
Clinical Scenario
This protocol addresses patients with atherosclerotic lower limb peripheral arterial disease in the intermittent claudication stage (Rutherford grade I–III; Fontaine stage IIa and IIb): exertional leg pain in the calf, thigh, or buttock that does not occur at rest and resolves within 10 minutes of stopping activity.
These patients adhere to best medical treatment but continue to experience lifestyle-limiting claudication despite first-line management.
First-Line Therapy That Has Not Met Its Goals
The first treatment step — risk factor management, best medical treatment, and a supervised exercise programme — has been established. This included single antiplatelet therapy (clopidogrel or aspirin), high-intensity statin therapy (atorvastatin or rosuvastatin), stepwise antihypertensive therapy (ACE inhibitor or angiotensin receptor blocker, calcium channel blocker, and thiazide-like diuretic as needed), diabetes management with an SGLT2 inhibitor or GLP-1 receptor agonist where indicated, and smoking cessation with behavioural intervention (varenicline or bupropion).
After reassessment at three to six months, the primary goal of improved maximum and pain-free walking distance has not been reached — triggering escalation to the next step.
Next Step: Walking-Improvement Pharmacotherapy
For patients who remain limited by claudication despite adhering to best medical treatment and exercise therapy, a specific pharmacological agent may be added to ongoing management with the aim of improving walking distance — subject to a structured reassessment to determine whether treatment should continue. The complete protocol specifies which agents apply and the criteria for continuing or stopping.
The treatment goal is improved maximum and pain-free walking distance, reassessed within three to six months of starting therapy.
References
DOI: 10.1016/j.ejvs.2023.08.067
- atherosclerotic lower extremity peripheral arterial disease (PAD, see also section 2.1) falling within the following clinical stages: (1) asymptomatic lower limb PAD (Rutherford grade 0/Fontaine stage I); and (2) intermittent claudication (IC, Rutherford grade I–III/Fontaine stage IIa and IIb).
- exertional calf pain that does not begin at rest, does not resolve during walking activity, and resolves within 10 minutes of rest.
- For patients with lifestyle limiting intermittent claudication who adhere to best medical treatment including exercise therapy, cilostazol or naftidrofuryl oxalate should be considered, to improve walking distance, but treatment should be stopped after three to six months of therapy if no improvement has been noted.